Can Seroquel Be Used for Major Depressive Disorder?
Yes, Seroquel (quetiapine extended-release) can be used for major depressive disorder, but only as adjunctive therapy to antidepressants—not as monotherapy—and it is FDA-approved specifically for this indication. 1
FDA-Approved Indication
The FDA label for Seroquel explicitly states that quetiapine XR is indicated for the acute treatment of depressive episodes associated with bipolar disorder, not unipolar major depressive disorder (MDD) 1. However, quetiapine XR has been FDA-approved as adjunctive treatment (add-on to antidepressants) for MDD in patients who have inadequate response to antidepressant monotherapy 2, 3.
When to Use Quetiapine in MDD
Use quetiapine XR 150-300 mg/day as add-on therapy when:
- A patient with MDD has failed to achieve adequate response after 6-8 weeks of antidepressant monotherapy at therapeutic doses 4
- The patient continues to have significant depressive symptoms despite adherence to first-line antidepressant treatment
- You have ruled out other causes of treatment resistance (medication non-adherence, substance use, medical comorbidities)
Evidence Base
Two large randomized controlled trials demonstrated that quetiapine XR 300 mg/day (and in one trial, 150 mg/day) as adjunctive therapy significantly reduced depressive symptoms compared to antidepressant plus placebo 2. The numbers needed to treat were 8-9 for the 300 mg dose and 11-18 for the 150 mg dose 2. Meta-analysis of monotherapy trials showed efficacy, but this is not the FDA-approved use 5.
Critical Caveats and Safety Concerns
Do not use quetiapine as monotherapy for unipolar MDD—this is off-label and not supported by FDA approval, despite research evidence 1.
Black box warnings apply:
- Increased mortality in elderly patients with dementia-related psychosis (quetiapine is NOT approved for this population) 1
- Increased risk of suicidal thoughts and behaviors, particularly in patients under age 24—monitor closely within 1-2 weeks of initiation 1
Common adverse effects that limit tolerability:
- Sedation, somnolence, and dizziness are very common
- Weight gain and metabolic changes (hyperglycemia, dyslipidemia) consistent with atypical antipsychotics 5, 2
- Discontinuation rates due to adverse events are significantly higher than placebo (RR 2.90) 5
Monitor patients for:
- Metabolic parameters (weight, glucose, lipids) at baseline and regularly during treatment
- Emergence of suicidal ideation, especially in the first 1-2 months 4
- Sedation that may impair function
Dosing Strategy
Start quetiapine XR at 50 mg once daily at bedtime, then:
- Day 2: 150 mg
- Day 3 onward: 150-300 mg/day (target dose range for MDD adjunctive therapy) 1
Continue the existing antidepressant at its therapeutic dose while adding quetiapine.
Alternative Approaches to Consider First
Before adding quetiapine, the American College of Physicians guidelines recommend considering 4:
- Switching to a different second-generation antidepressant (similar efficacy among SGAs)
- Adding cognitive behavioral therapy (CBT has similar efficacy to antidepressants with fewer adverse effects) 6
- Optimizing the dose of the current antidepressant if not at maximum therapeutic dose
- Augmentation with other agents (bupropion, buspirone) which have evidence for second-step treatment 7
Bottom Line
Quetiapine XR is a legitimate FDA-approved option for treatment-resistant MDD as adjunctive therapy, but the high rate of metabolic and sedative side effects means it should be reserved for patients who have failed other augmentation strategies or who cannot tolerate alternatives. The balance of efficacy versus tolerability is modest—acceptability (overall discontinuation rate) is not superior to placebo 5. Always obtain informed consent discussing metabolic risks and monitor appropriately.